Based on nitroimidazole compounds, a specific hypoxia probe named 18F-PEG3-ADIBOT-2NI-GUL targets the prostate-specific membrane antigen (PSMA) and can accurately display hypoxic regions within prostate cancer [126]. This evidence concerns the gene FOLH1 and prostate carcinoma.